Clinical phase III study of cimetropium bromide (DA3177) on the pain with upper urinary calculus : a double-blind study in comparison with scopolamine butylbromide. DA3177 Study Group

A double-blind study was conducted to evaluate the efficacy, safety and usefulness of cimetropium bromide (DA3177) in the patients with pain caused by upper urinary calculus at a daily dose of 75 mg t.i.d. (Group D, 97 patients) in comparison with scopolamine butylbromide at a daily dose of 60 mg t....

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 43(1997), 7 vom: 06. Juli, Seite 525-38
1. Verfasser: Ohkawa, T (VerfasserIn)
Weitere Verfasser: Morimoto, S, Okuyama, A, Yoshioka, T, Kishimoto, T, Kurita, T, Ikoma, F, Itatani, H, Koide, T, Ogawa, N
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1997
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Clinical Trial Clinical Trial, Phase III Comparative Study English Abstract Journal Article Multicenter Study Randomized Controlled Trial Parasympatholytics Scopolamine Derivatives cimetropium mehr... 1N3H74AYTK Butylscopolammonium Bromide 2Z3E1OF81V